- Group: Rare Disease Research Unit
- Location: Cambridge, MA
I joined Pfizer in 2013 and currently serve as Senior Director and Patient Advocacy Lead in Pfizer’s Rare Disease Research Unit. I am a healthcare professional with experience in patient advocacy, public affairs, program development, medical communications/education, basic and clinical research in pharmaceutical and academic clinical settings. I lead the strategic planning and implementation of collaborations with third party patient advocacy groups in support of the Rare Disease Research Unit’s programmatic areas of priority. In my role, I am external facing, engaging with rare disease patient advocacy groups to integrate their expertise and expertise into our discovery and development plans to drive our early drug development programs. I am also internal facing, helping to drive alignment and communication among cross-functional colleagues advancing our science and programs along the rare disease drug development continuum with rare disease patient communities.
Prior to joining Pfizer, I have built or joined patient advocacy teams in several biopharmaceutical companies, operationalizing these roles in various functions.
I am professionally trained as a Genetic Counselor, having spent 10 years in academic medicine as a Genetic Counselor at both New York Presbyterian Hospital-Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center before entering industry. I provided genetic counseling services, supported basic and clinical research programs, and coordinated comprehensive care programs to children, families and individuals with inherited hematologic and ophthalmic conditions.
I have lectured internationally in both academic and corporate roles. I am an author on more than 20 peer-reviewed publications.
I received my BA from Swarthmore College and Masters of Science in Human Genetics from Sarah Lawrence College.
- Parent and adult patient attitudes about gene therapy as a therapeutic option for Duchenne muscular dystrophy. Poster presented at the ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD. Peay H, Fischer R, Beaverson K, Morris C, Hesterlee SE, Ricotti V, Martin A, Rensch C, Ward H, Mansfield CA, Smith E. https://www.ispor.org/Event/ProgramList/2018Baltimore?type=Poster&sess=V&acode=PSY
- The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact. European Journal of Human Genetics. 2017 Nov; 25:1293–1302. Hanns Lochmüller, Josep Torrent i Farnell, Yann Le Cam, Anneliene H Jonker , Lilian PL Lau, Gareth Baynam, Petra Kaufmann, Hugh JS Dawkin, Paul Lasko, Christopher P Austin and Kym M Boycott on behalf of the IRDiRC Consortium Assembly. (Acknowledgements: K. Beaverson). https://www.nature.com/articles/s41431-017-0008-z
- The Role of Patient Advocacy in Drug and Device Development for Rare Diseases. ACRP-The Monitor Magazine. 2010 April. Beaverson K, Frestedt J, Saltonstall P, Engel PA.
Sarah Lawrence College, Masters of Science in Human Genetics, 1996
Swarthmore College, Bachelor of Arts, 1989
AWARDS & HONORS
Pfizer Rare Impact Award, 2017
Pfizer Legal Commitment Award: Be Supportive, 2017
Pfizer WE Upjohn Prizes (x6), 2016-2018
Boehringer Ingelheim Reach Excellence in Action Award, 2011